What We Treat

At the Aflac Cancer and Blood Disorders Center, our team is highly skilled and experienced in treating children and young adults with all forms of childhood cancer and blood disorders—from the most common to those rarely seen outside of the top pediatric centers. We treat:


Blood disorders

  • Hemophilia
  • Thrombosis
  • Other coagulation and bleeding disorders
  • Sickle cell disease
  • Thalassemia
  • Bone marrow failure syndromes
  • Other red blood cell disorders, including acute and chronic anemia
  • White blood cell disorders

Services We Offer

Comprehensive programs

  • Cancer Program: We are home to one of the top childhood cancer centers in the country. We have doctors who are skilled in treating all forms of cancer, including leukemia, lymphoma, brain tumors and solid tumors. 
  • Blood Disorders Program: We care for more than 2,500 children with sickle cell disease, hemophilia and other blood disorders each year. This includes more than 1,700 children with sickle cell—making us the largest pediatric sickle cell program in the country.
  • Blood and Marrow Transplant Program: As one of the top pediatric BMT programs in the country, we provide expertise in autologous and allogeneic transplants. We are a national leader in transplanting children with sickle cell disease—we have cured more than 70 children.
  • Developmental Therapeutics Program: Our team focuses on the discovery and creation of new treatments for children with cancer.
  • Survivor Program: We provide nationally recommended, long-term follow up care and resources for survivors of pediatric cancer and blood and marrow transplant.
  • Supportive Care Clinic: We help children who have serious illnesses and their families live as well as possible.
  • Cancer Predisposition Program: We treat children under the age of 18 who are at risk for developing cancer due to a cancer predisposition syndrome, a family history of cancer or a diagnosis of a rare type of cancer. 

Innovative research

The Aflac Cancer Center is committed to excellence and innovation in pediatric cancer and blood disorders research. We are home to one of the largest clinical trial programs in the country—offering our patients access to some of the most novel treatment options in the country.

Find a clinical trial

Clinical trial highlights

The Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta is proud to have participated in the chimeric antigen receptor (CAR) T cell clinical trials for the treatment of pediatric CD19 positive acute lymphoblastic leukemia (ALL) sponsored by Novartis, that resulted in U.S. Food and Drug Administration (FDA) approval of this ground breaking therapy (Tisagenlecleucel—trade name Kymriah).

We are one of a limited number of centers designated as a certified treatment site. Our team has developed expertise in the delivery of this therapy, treating patients across Georgia and from surrounding and remote states. In addition, our research team is adapting this concept to target other brain tumors and neuroblastoma, which we hope to have in open clinical trials to provide options to patients with resistant disease.

AflacLL1602/ENCERT: A Phase 1 trial using everolimus in combination with nelarabine, cyclophosphamide and etoposide in relapsed T cell lymphoblastic leukemia and lymphoma (T-ALL/T-LLy)

Current therapy options for patients with relapsed T-ALL or T-LLy yield only a 30 percent complete remission rate. The addition of everolimus, an mTOR inhibitor with activity in T cell disease, may improve those rates. The study's main goal is to determine a safe pediatric dose of everolimus and establish a safety profile for everolimus when given in combination with standard chemotherapy.

AflacST1603: A Phase 1 study using nab-paclitaxel (Abraxane) in combination with gemcitabine for pediatric relapsed and refractory solid tumors

Relapsed and refractory non-central nervous system (non-CNS) solid tumors have poor outcomes and novel therapies are needed. We hypothesize the combination of gemcitabine and nab-paclitaxel, an albumin-bound, solvent-free taxane that allows higher dosing and shorter infusion duration than solvent-bound taxanes, as well as increased drug delivery to tumors through increased albumin-initiated transcytosis, will improve the anti-tumor efficacy observed with gemcitabine and docetaxel in relapsed and refractory solid tumors. The study's main goal is to determine a safe pediatric dose of nab-paclitaxel, in combination with gemcitabine, and define a toxicity profile for this combination of chemotherapy.

AflacLL1401: A Phase 1 study using dasatinib in combination with chemotherapy for relapsed or refractory core-binding factor acute myeloid leukemia (NCT02680951)

Acute Myeloid Leukemia (AML) patients with core-binding factor mutations often have an increase in c-KIT protein. Lab and other studies suggest that by targeting this protein, dasatinib may prevent AML cells from growing and leading to leukemic cell death. The study's main goal is to determine a safe pediatric dose of dasatinib and establish a safety profile for dasatinib when given in combination with standard chemotherapy.

AflacST1402: A Phase I study using simvastatin in combination with topotecan and cyclophosphamide in relapsed and/or refractory pediatric solid and CNS tumors (NCT02390843)

Independent of cholesterol inhibition, simvastatin has been found to inhibit signal transducer and activator of transcription 3 (STAT3). STAT3 is a protein that stimulates chemotherapy resistance, which is a major cause of treatment failure and death among pediatric and adolescent patients. The study's primary objective is to define the toxicity of high dose simvastatin in combination with chemotherapy to treat solid tumors with abnormal STAT3 activation by restoring tumor sensitivity to routine chemotherapeutic agents.

AflacST1501: A Phase 1 study using abemaciclib in children with newly diagnosed diffuse intrinsic pontine glioma, and in children with recurrent and refractory solid tumors, including malignant brain tumors (NCT02644460)

Abemaciclib represents a selective and potent CDK4/6 dual inhibitor with broad anti-tumor activity. There is existing biologic data demonstrating dysregulation of the CDK4/6 pathway in pediatric high-grade tumors, including malignant brain tumors. Presently, there are not any established treatments that provide effective therapy for patients with progressive disease or patients with newly diagnosed diffuse intrinsic pontine gliomas (DIPG). Abemaciclib is an attractive agent for these patients, given the strong preclinical data on blood-brain barrier penetration, oral bioavailability and its anti-tumor activity. The study's primary objective is to estimate the maximum tolerated dose of abemaciclib in this patient population.

AflacST1502: A Phase II study of sirolimus in combination with metronomic chemotherapy in children with recurrent and/or refractory solid and CNS tumors (NCT02574728)

Sirolimus is a potent immunosuppressive drug that has been found to inhibit cell growth and have anti-tumor activity in previous studies involving pediatric solid tumors. This Phase II study will investigate the time of progression in children with recurrent and refractory solid tumors, including brain tumors, when oral sirolimus is given in combination with metronomic chemotherapy.

Our Unique Approach

The Aflac Cancer and Blood Disorders Center is one of the leading childhood cancer and blood disorders programs in the country. Combining the latest proven technology and research with a caring, child-friendly approach, makes the Aflac Cancer Center a top choice for the treatment of common and complex cancer and blood disorder conditions.

Learn more about what makes Children's special

Nature journal to feature Wilbur Lam, MD

The February issue of Nature journal will feature Wilbur Lam, MD, physician at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta, for developing a new technology that helps physicians study bleeding holistically. With support from his biomedical engineering lab at Emory University School of Medicine and Georgia Institute of Technology, Dr. Lam has developed microchip technology that creates an artificial blood vessel that has the capability to open up and bleed, allowing physicians to better understand what happens during the clotting process for patients with blood disorders. His research is funded by a National Institutes of Health (NIH) U54 grant.

Meet the Team

Meet our Cancer and Blood Disorders team

Helpful Resources

New patient forms

Request a new patient appointment

Before your visit

Learn how to prepare for your visit to the Aflac Cancer Center, including information about our transitional housing options for families traveling from outside of Atlanta.

Get information and tips

Camps, events and support groups

Camps, retreats and other events offer many therapeutic benefits for children and families who are dealing with serious illness.

Camps, events and support groups

Second opinions and international services

We understand you want to be certain your child is receiving the best possible treatment available anywhere in the world. Second opinions can help provide the information you need to make an informed decision about the treatment for your child. For families traveling outside the U.S., we are here to help meet your unique needs and challenges.

Learn more about our second opinion services

Learn more about our international services


Learn how you can help make a difference in the life of a child battling cancer or a blood disorder.

Join the fight against childhood cancer and blood disorders

Learn more about how Aflac supports us


Egleston hospital

1405 Clifton Road NE

Atlanta, GA 30322

Hughes Spalding hospital

35 Jesse Hill Jr. Drive SE

Atlanta, GA 30303

Scottish Rite hospital

1001 Johnson Ferry Road NE

Atlanta, GA 30342-1605

Children's Medical Office Building at Scottish Rite hospital

5461 Meridian Mark Road NE

Atlanta, GA 30342-1654